Acute Myeloid Leukemia Treatment From Chemo to Stem Cell Transplant

acute-myeloid-leukemia-treatment-options
Dr. Navaneeth P S
Doctor
๐Ÿ“… Published: November 16, 2026
๐Ÿ”„ Updated: November 16, 2026
โœ… Medically Verified
โฑ 8 min read

Acute Myeloid Leukemia Treatment From Chemo to Stem Cell Transplant

๐Ÿ’ก
Key Takeaways
The most important points from this article
โœ“

Acute myeloid leukemia requires prompt diagnosis and treatment; a two-phase strategy combining induction and post-remission therapy offers the best outcomes.

โœ“

Treatment choice depends on your age, fitness, disease genetics (mutations in FLT3, IDH1/2, TP53), and whether you are eligible for stem cell transplantation.

โœ“

Intensive chemotherapy (7+3) achieves remission in 60-80% of younger patients but requires hospitalization and close supportive care during low blood-count periods.

โœ“

Targeted therapies and venetoclax combinations offer less-intensive options for older adults or those with comorbidities, improving access to effective treatment.

โœ“

Allogeneic stem cell transplantation offers the strongest potential for long-term remission or cure in high-risk AML, with specialized centers like ours in Kozhikode providing comprehensive care.

Acute myeloid leukemia (AML) is a blood cancer where immature myeloid cells multiply uncontrollably, crowding out healthy blood cells. Treatment has evolved significantly over the past decade, offering patients multiple pathways specific to age, fitness, and disease characteristics. Understanding your options helps you and your doctors make informed decisions about your care.

This guide explains each acute myeloid leukemia treatment option, how doctors choose between them, and what the pathway looks like at Baby Memorial Hospital (BMH) in Kozhikode, Kerala.

Quick answer: The main acute myeloid leukemia treatment options are induction chemotherapy (usually cytarabine plus an anthracycline), targeted drugs matched to gene changes, lower-intensity regimens such as venetoclax with azacitidine for older or unfit patients, consolidation chemotherapy, and allogeneic stem cell transplant. The right mix depends on age, fitness, genetics and response.

What Is AML and Why Does Treatment Start So Fast?

Acute Myeloid Leukaemia (AML) begins in the bone marrow, where abnormal myeloid cells (blasts) crowd out healthy red cells, platelets and white cells. Some people arrive with very high leukemia cell counts that disturb blood flow, a problem called leukostasis, which needs immediate treatment with chemotherapy or leukapheresis.

Before choosing a regimen, doctors need a bone marrow biopsy plus cytogenetic and molecular tests. Those results are not paperwork; they decide which drugs are even appropriate.

How Doctors Choose Your AML Treatment Plan

Acute myeloid leukaemia (AML) treatment is tailored to your diagnosis, overall health and treatment goals. Your haematologist evaluates several factors to determine whether chemotherapy, targeted therapy or a stem cell transplant is most appropriate.

The main considerations include:

  • Age and overall health: Your fitness, existing medical conditions and ability to tolerate intensive chemotherapy help determine the treatment approach.
  • AML subtype and genetic changes: Tests for mutations such as FLT3, IDH1 and IDH2, along with markers such as CD33, can identify patients who may benefit from targeted therapies.
  • Response to initial treatment: Bone marrow tests assess how well leukaemia responds to the first treatment cycle. Persistent disease or a higher risk of relapse may prompt doctors to consider a stem cell transplant.
  • Donor availability: A suitable matched sibling or unrelated donor may make an allogeneic stem cell transplant possible.
  • Personal preferences: Your quality-of-life priorities, treatment tolerance and goals are important when discussing the available options.

Your treatment plan may change as test results and treatment responses become clearer.

Main Treatment Approaches for Acute Myeloid Leukemia

AML treatment typically follows a two-phase strategy: induction therapy aims to achieve remission by killing as many leukemia cells as possible, and post-remission therapy (consolidation or transplant) aims to eliminate remaining disease and prevent relapse. The main treatment modalities are intensive chemotherapy, hypomethylating agents for older or unfit patients, targeted therapies directed at specific genetic mutations, and stem cell transplantation for eligible candidates.

Treatment TypeBest ForGoal
Intensive chemotherapy (7+3)Younger, fit patientsRapid remission, eligible for transplant
Hypomethylating agentsOlder or unfit patientsModest remission, tolerable side effects
FLT3/IDH inhibitors + chemotherapyFLT3 or IDH1/2 mutationsImproved survival, less toxicity
Venetoclax combinationsTP53, other mutationsNon-intensive option with good outcomes
Stem cell transplantationAfter remission, if eligibleLong-term remission and potential cure

Your doctor selects the best approach after reviewing your blood work, bone marrow biopsy results, and fitness assessment.

Phase 1: Induction Chemotherapy

The 7+3 regimen

For younger, healthy adults, induction typically combines cytarabine given continuously for 7 days with an anthracycline such as daunorubicin or idarubicin on the first 3 days, which is why it is called 7+3.

Adding a targeted drug

If leukemia cells carry an FLT3 mutation, midostaurin or quizartinib may be added. If they carry CD33, gemtuzumab ozogamicin may be added.

What the hospital stay is really like

Induction wipes out normal marrow cells along with leukemia cells, so counts fall dangerously low for a few weeks. Expect antibiotics, transfusions and sometimes growth factors. About one to two weeks after chemotherapy, a repeat marrow test checks response; remission is likely only if blasts are 5% or less of the marrow. Most patients reach remission after the first round, but some need reinduction.

Phase 2: Consolidation and Stem Cell Transplant

Remission induction rarely clears every cell, so consolidation follows. For patients under about 60, options include several cycles of high-dose cytarabine (HiDAC, roughly every four weeks for three or four cycles), an allogeneic donor transplant, or an autologous transplant.

Allogeneic versus autologous. In an autologous transplant, a patient's own stem cells are collected and returned. In an allogeneic transplant, stem cells come from a sibling, another family member or an unrelated donor after HLA compatibility testing.

The trade-off. Transplants cut relapse risk more than standard chemotherapy, but they bring a higher chance of serious complications, including graft-versus-host disease and infection. Good prognostic genetics may lead doctors to hold transplant in reserve; adverse genetics may move it earlier.

RUA Assistant
Your Medical Assistant
Get expert guidance from leading medical specialists.

Treatment for Older Adults or Those Unfit for Intensive Chemo

Intensive chemotherapy can do more harm than good for some older or frail patients. Alternatives include low-dose cytarabine, azacitidine or decitabine, often combined with venetoclax. Mutation-matched options include ivosidenib (IDH1), enasidenib (IDH2), and quizartinib or sorafenib with azacitidine or decitabine. Age alone should never close the door; a fitness assessment should.

What to Expect During Your Treatment Journey

Your AML treatment journey typically unfolds over months. After diagnosis confirmation through bone marrow biopsy and genetic testing, you meet with your oncologist to discuss treatment options based on your specific disease and health status. If you receive intensive chemotherapy, hospitalization lasting two to four weeks allows close monitoring of your blood counts, vital signs, and organ function. Weekly or twice-weekly outpatient blood tests track your response; bone marrow biopsy around day 14-21 confirms remission status.

During low blood-count periods, you take precautions: avoid crowds and raw foods, report fever or bleeding immediately, and maintain strict hygiene. Nausea, fatigue, and appetite loss are common; your care team offers anti-nausea medications and nutritional support. Once remission is achieved, consolidation therapy (additional chemotherapy or transplant) follows over weeks to months. Recovery varies: many patients return to normal activities within three to six months post-treatment, though fatigue may persist longer. Support from social workers, nutritionists, and mental health counselors helps you navigate this challenging period.

How NAVA Cancer Institute Plan AML Treatment

Baby Memorial Hospital (BMH), established in 1987, provides haematology, haemato-oncology and bone marrow transplantation (BMT) services for patients with acute myeloid leukaemia (AML). Its care pathway combines diagnostic evaluation, chemotherapy, targeted therapy and transplant planning, depending on the patient's condition and disease characteristics.

At BMH Kozhikode, NAVA Cancer Institute supports multidisciplinary cancer care through tumour board discussions, molecular profiling and coordinated treatment planning. These assessments help doctors select treatment based on AML subtype, genetic mutations, response to initial therapy and transplant eligibility.

What patients can expect

  • Diagnosis and risk assessment: Review of blood counts, bone marrow biopsy, flow cytometry, cytogenetic analysis and molecular testing to characterise AML.
  • Individualised treatment: Chemotherapy and targeted drugs where indicated, based on genetic findings and overall fitness.
  • Response monitoring: Repeat bone marrow assessment to evaluate remission and guide the next phase of treatment.
  • Transplant planning: Donor evaluation and HLA typing when allogeneic stem cell transplantation is appropriate.
  • Specialist guidance: Dr Shinto Francis Thekkudan, Chief and Senior Consultant, brings clinical haematology training and stem cell transplantation experience to the department.

NRI and Gulf families can share medical reports through BMH's International Patients service for preliminary guidance. Request a written estimate covering diagnostics, hospitalisation, medicines and potential transplant costs before making travel arrangements.

Also Read: Which Is the Best Oncologist in Kozhikode for Expert Cancer Treatment?

Conclusion

Acute myeloid leukemia treatment has transformed dramatically, moving beyond one-size-fits-all chemotherapy to personalized approaches combining intensive and targeted therapies tailored to your disease genetics and overall health. Whether you are a candidate for intensive induction, targeted combinations, or non-intensive regimens, early diagnosis and prompt treatment initiation significantly improve survival. Discussing your goals, concerns, and lifestyle priorities with your oncology team helps shape a treatment plan that balances aggressive disease control with manageable side effects and quality of life.

Have your reports ready? Chat with the BMH medical assistant on WhatsApp.

Medical disclaimer: This article is for general information and does not replace advice from a qualified doctor. Treatment for acute myeloid leukemia depends on individual diagnosis, test results and health. Do not start, stop or change any treatment without consulting your haematologist or oncologist.

Frequently Asked Questions

Acute myeloid leukemia (AML) develops rapidly over days to weeks with immature blasts crowding the bone marrow, requiring urgent treatment. Chronic myeloid leukemia (CML) develops slowly over months to years with more mature cells; it is often managed initially with oral targeted therapy. AML generally requires more intensive treatment and hospitalization.

Source Links

National Institutes of Health: Adult Acute Myeloid Leukemia Treatmenthttps://www.cancer.gov/types/leukemia/patient/adult-aml-treatment-pdq